Try our Advanced Search for more refined results
Life Sciences - September, 2018
280 articles
- Supreme Court Cheat Sheet: 8 Cases To Watch
- Health Hires: Carlton Fields, Crowell & Moring, GCs
- SEC Accuses Drugmaker of Venomous Deceptions
- FDA Halts Imports From Chinese Drug Co. Over Impurities
- PE Firms Let Out Of Zimmer Investors' Stock-Drop Suit
- Compounding Pharmacy, Owner Ink $1.2M Deal In FCA Case
- Swimmer Cleared Of Doping After Meds Found Contaminated
- 9 Firms To Guide IPOs Totaling $779M To Launch October
- Sensipar Exclusivity Expires, Ending Amgen's DC Circ. Fight
- Walgreens, Kroger Have No Right To Sue Over Remicade: J&J
- Fed. Circ. Partly Revives Bard Medical Device Patents
- Skadden, Latham Lead $152.2M In Biotech, Tech Startup IPOs
- Opioid Task Force Arrests 76 After Raid On Tribal Land
- Stryker Settles SEC's Latest FCPA Claims For $7.8M
- Ex-Salix CFO Pays $1M To End Claims He Misled Investors
- Teva Revives Patent Fight After FDA OKs Lilly's Migraine Drug
- The Evolution Of Conspiracy Personal Jurisdiction
- Dismissing FCA Cases: The Granston Memo In Action
- Kessler Topaz Tapped To Lead Celgene Investor Suit
- KDB Expands Intellectual Property Force With 5 Hires
- Bull Stud Co. Wins $5M Fees, Costs In Semen-Sorting Row
- 6th Circ. Revives Esperion Investor Suit Over Cholesterol Drug
- Texas Man Still Barred From Selling 'Miracle' Supplement
- Five Cos. Price IPOs Totaling $483M Led By 3 Biotech Firms
- Pa. Doc's TCPA Row With Sanofi Timely, 3rd Circ. Told
- ActiveCare Ch. 11 Sale Delayed Amid Potential Claim Issues
- Construction Co. Gets Army Facility Contract Suit Trimmed
- Lilly Migraine Med's Uncertain Future Kills Teva's Patent Suit
- Ariosa Prior Art Appeal Relies On Old Law, Illumina Says
- Pa. Can't Hide Medical Marijuana Permit Reviewers' Names
- Suit From CVS, Others To End Opioid Tribal Court Case Axed
- Fidelity Leads Ultrasound Co.'s $250M Funding Round
- Al Jazeera Must Produce Docs In Doping Documentary Suit
- How Corporate Reputation Risk Is Exacerbating D&O Liability
- Monsanto Exec Named Bayer's US General Counsel
- Vioxx Economic Loss Counsel Win $4.2M In Attys' Fees
- McKesson Is Roped Into Generic-Drug Price-Fixing Row
- J&J Fights $245M Faulty Hip Implant Judgment
- PwC Escapes Valeant Investors' $80B Price-Gouging Suit
- Medco Exec Tells 3rd Circ. FCA Suit Based On Nonpublic Info
- 3 Firms Steer Alexion's Deal For VC-Backed Syntimmune
- Allergan Medicaid Rebate Suit Redo Denied At 3rd Circ.
- Brazilian Education Tech Co. Leads 4 IPOs Totaling $477M
- Express Scripts Overcharged Attys For Records, Suit Says
- 3rd Circ. Won't Revive Chinese Co.'s GSK Probe Suit
- Expert's Analyses Questioned In AbbVie Merger Cert. Row
- 2 Firms Steer Automation Co.'s $450M Genomics Buy
- Doctor DQ'd From Testifying About Opioids In Insys Case
- SEC Fires Warning Shot Against 'Short And Distort' Schemes
- Federal Courts Diverge On Bristol-Myers And Class Actions
- 5 More GC Tips For Succeeding As A New Associate
- Atty Lies Shouldn't Doom $200M IP Win, Merck Tells Justices
- USPTO Patent-Eligibility Revamp May Face Court Skepticism
- Opko Faces Wave Of Suits After SEC Pump-And-Dump Claims
- Hartig Seeks $3M In Attys' Fees In Product-Hopping Suit
- 'IV Cocktail' Ads Stir FTC To Prioritize Health Enforcement
- Sham Petition Suits Are Piercing Big Pharma's Antitrust Shield
- FTC Wins False Ad Suit Against Diet Pill Maker Roca Labs
- Investor Sues KMG Chemicals To Block $1.6B Cabot Merger
- Roche Escapes Stock-Drop Suit Over Cancer Drug Results
- Judging A Book: Block Reviews 'Tough Cases'
- Ex-NFLer Can't Ditch Pump-And-Dump Verdict At 9th Circ.
- Roundup MDL Seeks More NorCal Bellwether Cases For Trial
- Prosecutors Can Tell 3rd NECC Jury About Meningitis Pain
- Jury Deadlock Ends Latest Philly Mesh Case
- EHealthline.com Says $3.5M Award Row Should Be Paused
- Humira Kickback Claims Spawn Investor Suit Against AbbVie
- Amarin Sees Off-Label Claims Boosted By Study Results
- Janssen Gets $1M Risperdal Breast-Growth Verdict Flipped
- Communication Is Key To Quick ANDA Approvals, FDA Says
- Sanofi Allowed To Scrap Pain Cream Contract, Judge Says
- Vitamin C Importers Tell 2nd Circ. Price Fixing Voluntary
- Ex-Akebia Analyst Jailed For Ignoring Probation Calls
- Jury Deadlocks In J&J Trial Over Talc-Asbestos Claim
- Allergan's Discovery Buck-Passing Rejected In Opioid MDL
- Cancer Test Maker, Biotech Firm Prime IPOs Totaling $326M
- US-China Fight Shows No Sign Of Stopping As New Tariffs Hit
- 8 Innovative Ways To Empower Jurors
- PTAB Upholds Alcon Patent For Glaucoma Treatment
- 15 Firms To Lead IPOs Exceeding $1.1B Amid Peak Season
- Athenex Gets FDA Compounding Policy Wrong, Amicus Says
- Health Hires: DLA Piper, Baker Donelson, Pharma GCs
- Consumer Seeks Full 3rd Circ. Redo Of Toxic Talc Ruling
- Allergan, Tribe Sue Pharma Co. Over Restasis Patent
- Atty Can't Shake $1.76M Suit Over Alleged Consulting Scam
- MabVax Stock Actions Stand Amid Pump-And-Dump Claims
- Sterigenics Hid Cancer Risk Of Emissions, Ill. Residents Say
- Class Attys Get $35M Of $105M Lidoderm Pay-For-Delay Deal
- Fosamax MDL Revival Must Be Nixed, US Tells High Court
- Wage-And-Hour Suit Against J&J Headed Back To State Court
- Cloud Computing Clearly The Future For Small Firms
- Telemedicine — The Next Frontier For DOJ Scrutiny?
- New MDL Needed For 'Opioid Babies,' Attys Say
- CORRECTED: Attys Sanctioned $655K After $645M Medical Device Row Loss
- Counsel Needs 'Backup' For Payment In $4.75M Vertex Deal
- 7th Circ. Will Not Rehear Suit Against GSK Over Atty's Suicide
- FTC Settles With 'IV Cocktail' Seller Over Health Claims
- Houston Pill Mill Doc, Clinic Chief Each Get 35 Years In Prison
- J&J Can't Escape Calif. Talc Warning Label Suit
- Purdue Pharma Must Face NH's Suit Over Opioid Marketing
- Leveraging Today's Lateral Associate Market
- Opioid Bill Lacks Funding To Make Lasting Impact
- 'One A Day' Will Not Keep Plaintiffs Away
- Trustee Objects To Debt Forgiveness In ActiveCare's Ch. 11
- UnitedHealthcare Can't Take Back Cephalon Antitrust Deal
- AngioDynamics Says Rival Must Stay In $145M Damages Row
- Mass. Doc Dodges Prison After Giving Patient Info To Drug Co.
- Pfizer Unit, Teva Must Face Effexor Antitrust Litigation
- SEC Accuses Breast Implant Maker's Ex-CEO Of Stock Fraud
- Eli Lilly's Animal Health Unit Elanco Raises $1.5B In IPO
- No Need To Reconsider Immunity At PTAB, Fed. Circ. Hears
- Deals Rumor Mill: Tencent Music, Linde, Coca-Cola
- FDA Warning Wire: Beer Brewing At Lab, Mice At Egg Giant
- Allergan Loses 'Meritless' Bid To Gut Restasis Antitrust MDL
- French Medical Device Maker Sued Over Clot Filter Failure
- Patents At The High Court: What To Watch In The New Term
- US Finalizes Hefty Tariffs On Chinese Sodium Compound
- Novartis Warping Kickback Standard In FCA Case, DOJ Says
- Back To School: Stanford's Jeff Fisher Talks Supreme Court
- Genetic Data Holds Opportunities And Risks For Litigants
- Monsanto Fights To Get $289M Verdict Tossed Or A New Trial
- Merck Workers Defend Class Claims In $250M Sex Bias Suit
- Boston Scientific Faces Chancery Suit For Ending $275M Deal
- 2 Risperdal Cases Greenlighted For Punitive Damages Trials
- Labaton, Levi Vie For Lead Role In Prothena Stock-Drop Row
- AbbVie Kickbacks Tainted $1.3B In Humira Claims, Calif. Says
- Ulthera Appeals PTAB Decision Upholding Skin Care Patent
- 7th Circ. Has Chance To Cut Off 'Mootness Fee' Merger Cases
- J&J Cut Corners, Pelvic Mesh Jury Hears At Philly Trial's End
- Deals Rumor Mill: GSK, ADC Therapeutics, Haidilao
- Fed. Circ. Ruling Takes 'Blocking Patents' To New Places
- Clovis To Pay $20M To End SEC Claims Over Cancer Drug
- Six Cos. Launch IPOs Totaling $465M Led By Biotech Firms
- Ore. Pot Biz Owner Gets 7 Months For Federal Tax Crimes
- Biotech Cos. Must Respect Coexisting Gene Editing Patents
- SEC Settles With Alleged Chicago Penny Stock Fraudster
- Orexigen Decision At Odds With High Court Jurisprudence
- Smith & Nephew To Pay $10.5M To Settle Knee Implant IP Row
- No Kickback Fines For Implant Refunds, HHS Watchdog Says
- Biopharm Co. Investors Sue Directors In Chancery Over Pay
- J&J Talc Supplier Makes Last-Second Deal In Asbestos Trial
- J&J Wages New Fight Over Asbestos In Talc After $117M Loss
- Deals Rumor Mill: Uber, Bayer, QIA
- Opioid MDL Stakes Rise For Pharmacy Benefit Cos.
- Armstrong Teasdale Heads Into Philly With Montgomery Chair
- Gleevec Buyers Say 1st Circ.'s Dismissal Misread Patent Law
- Insys Wants Out Of Off-Label Fentanyl Prescription Suit
- Court Sanctions Nutrition CEO, Atty Over False Patent Claims
- Sport Supplement Co., Consumers Settle Deceptive Label Suit
- What Manufacturers Should Know About Triclosan Findings
- Teva Looks To Escape Proposed Price-Hike Class Action
- Valeant Must Face Deceptive Pricing Claims By Hedge Funds
- Calif.'s New Rules For Lawyers Move Closer To ABA Model
- Surveying The Cannabis Patent Litigation Landscape
- J&J Hit With Another Suit Over Alleged Talc-Related Death
- 14 Firms To Steer 8 IPOs Topping $3B As Busy Autumn Nears
- 2nd Ex-GSK Scientist Pleads Guilty In Chinese IP Theft Case
- Justices Told FDA's 'Smoking Gun' Sinks Fosamax MDL
- WilmerHale, Cooley Guide $100M Biotech IPOs
- McCarter & English Nabs Gibbons Product Liability Pro In NJ
- Biopharma Co. Principia Leads 3 IPOs Totaling $225.3M
- Takeda's £46B Shire Buy Gets Nod From Chinese Regulator
- FTC Told Impax Can't Justify Opana Reverse Payment
- Valeant, PwC Shed State Law Claims In Investors' Suit
- FDA Focus: What Axinn's Practice Chair Is Watching
- Relators Slam Teva's Quick Win Bid In Overpaid Speaker Suit
- Congressional Forecast: September
- Know The Limits To Atty Public Statements During A Trial
- J&J Must Pay $29M For Selling Talc With Asbestos, Jury Told
- Boston Joins In Suing Purdue, Others Over Opioid Epidemic
- FDA Never Saw Birth-Defect Tests On GSK Drug, Families Say
- Fed. Circ. Backs PTAB, Says Inventor's Catalog Dooms Patent
- Boehringer Snags Austrian Biopharma Co. In $245M Deal
- Allergan Looks To Keep CEO's Tribal Patent Docs Out Of MDL
- Deals Rumor Mill: Meituan Dianping, Takeda, Adobe Systems
- FTC's Public Hearings Will Be Valuable
- In Calif., Questions Remain On Law Firm Conflict Waivers
- A Chat With Faegre Client Development Chief Melanie Green
- DOJ Is Getting Creative, And Aggressive, On Opioids
- Trump Not In A Hurry To Broker Trade Peace With China
- Two Lidoderm Class Action Deals Worth $271M Get Final OK
- SEC Claims Mass. Broker Lied To Short Drug Co. By $1.3M
- Medline's Docs Not False, Judge Says In Catheter Design Row
- Law Schools Struggle To Find Themselves In Post-Recession Market
- Bausch Health, Actavis Strike Deal Over Generic Xifaxan
- Intuitive Surgical Investors Strike $42.5M Stock-Drop Deal
- Conflict Should DQ Katten In IP Row, Valeant Tells Fed. Circ.
- McDermott Snags Ex-HHS OIG Pro As Partner For DC Office
- Medical Co. Investors Want Final $5M Deal OK'd In IPO Row
- 1st Circ. Questions BioChemics Strategy In SEC Probe Case
- Intellectual Property Caught In US-China Trade Crossfire
- How A 'Lost Generation' Of Associates Bounced Back
- CRISPR Patent Ruling May Push Warring Sides To A Deal
- Hospitals Sue HHS For Slow-Walking 340B Penalties
- Out-Of-State J&J Talc Suits Tossed From Delaware Courts
- OTC Health Products Maker Hits Ch. 11 In Wake Of Recalls
- FDA Warning Wire: Plant Problems Behind Medtronic Recalls
- Judge Ends Bayer Battle Over 'Flanax' Trademark
- FDA's Former Top Atty Heads Back To Sidley Austin
- BioChemics Claims It Can Pay Chunk Of $17M SEC Judgment
- Akorn FDA Report Added To Fresenius Trial Record
- ResMed Rival Returns Fire In Sleep Aid Patent Battle At ITC
- Fla. Doc Gets 20 Years For 'Hospice-Level' Opioid Scripts
- Bristol-Myers Looks To Ax Investor Suit Over Clinical Trial
- Dechert Adds Life Sciences-Focused PE Atty In London
- Asbestos-In-J&J Talc Claims Withdrawn On Eve Of Trial
- Medical Device Maker Wins $645M In Rival Theft Case
- AbbVie Strikes Tentative Deal In Testosterone MDL
- Consumers Denied Cert. In False Ad Suit Over Diet 'Crystals'
- Akorn Says FDA Report Rehashes Data From Fresenius Trial
- Fed. Circ. Backs Decision Axing 4 Acorda MS Drug Patents
- Can BigLaw Avoid Another Associate Purge?
- 8th Circ. Backs $25K Atty Sanction In Enbrel Discovery Row
- NJ Doc Loses License Over Opioid Prescriptions, Insys Pay
- China Tells 2nd Circ. Vitamin C Exporters Followed Law
- Fed. Circ. Backs Harvard, MIT Over UC In CRISPR Patent War
- Fed. Circ. Revives Orexo's Opioid Addiction Treatment Patent
- Imprimis Sanctioned Again For Flouting Discovery Order
- Muscle Milk Buyers Get Partial Cert. In Nutrition Labeling Row
- Why State Marijuana-Impaired Driving Laws Need Reform
- When Courts Allow Changes To Hatch-Waxman 30-Month Stay
- Measuring The Recession's Toll On The Legal Industry
- Has BigLaw Recovered From The Financial Crisis?
- Ex-Teva Head Accused Of Role In $27M Pump-And-Dump Scheme
- Biogen Gets Win In Drug IP Fight As Judge Overrides Jury
- Impax Escapes Investors' Drug Price-Fixing Suit, For Now
- Suit Over Bayer's Twice-Daily 'One A Day' Gummies Revived
- Pipe Giant Tops 3 IPO Launches Surpassing $1B Combined
- States Back Tribe, Allergan Fed. Circ. Bid For PTAB Immunity
- Brand Battles: Hot Pockets, Adderall, Superman
- As Biz Opposes China Tariffs, Trump Says More On The Way
- Real Estate Rumors: Deutsche Bank, Citi, Allergan
- Health Hires: Pepper Hamilton, Perkins Coie, Davis Wright
- BTG Snags Irish Vascular Health Co. In $150M Deal
- St. Jude Ditches Patient's Defective Heart Valve Suit
- Amgen Suit Shows Limitations Of Biosimilar Safe Harbor
- Boston Biotech Exec Cops To Role In $12.7M Painkiller Fraud
- A Look At OIG's Medicare Exclusion Analysis Under FCA
- 3rd Circ. Says 'Buyer's Remorse' Can't Revive Toxic Talc Suit
- Church & Dwight Wins $10M In Pregnancy Test False-Ad Suit
- Reed Smith Widow Wants Full 7th Circ. To Consider GSK Suit
- Mylan Decries 'Hopeless Fishing Expedition' In EpiPen MDL
- The Bloody Saga That Made Theranos Finally Call It Quits
- Abiomed Seeks Quick Win In Fired Exec's $2.1M Equity Suit
- VC-Backed Upwork, Guardant File IPOs Totaling $200M
- Fed. Circ. Hands Win To Supernus Over Generic Seizure Drug
- Ex-Celator Employee Gets Prison For Insider Trading Scheme
- Monsanto Can't Round Up Chemical Docs From Advocacy Org
- Mylan Investors Push Back At Bid To Toss EpiPen Claims
- Ex-Akebia, Merrimack Analysts Want Conviction Tossed
- Oberland Capital Reaps $800M For Second Fund
- Lilly's Animal Health Unit Gears Up To Launch $1.4B IPO
- Ice Miller Welcomes Ex-Robinson Brog Partner In New York
- 7th Circ. Mulls Lack Of State Action In Fetal Tissue Law Row
- Lens Makers Fight Sanctions Over Defunct Facebook Page
- Gwyneth Paltrow's Co. Settles Vaginal Egg Health Claims Suit
- Tribes Can't Have Opioid Suits Sent To State Court From MDL
- Bio-Focused VC Firm Westlake Scores $320M 1st Fund
- Wine Spectator Hits 'Weed Spectator' With Trademark Suit
- PTAB Stands By Post-SAS Changes In Dartmouth Patent Case
- J&J, Janssen Win Mass. Risperdal Suit On Teen's Weight Gain
- Chinese News Aggregator Sets Price Range For IPO
- FDA Focus: What Morgan Lewis' Practice Chair Is Watching
- Getinge Dodges Subsidiary's Blood Pump Patent Fight
- 3rd Circ. Revives FCA Case Against PharMerica
- Feds Fight Claim That Expert Witness Double-Crossed Insys
- Generics Cos. Urge Fed. Circ. To Upend Depomed Patent Win
- Withers Lands Ex-Bryan Cave Arbitration Pro In NY
- McKesson Defends Right To $7M Of Disputed Orexigen Funds
- Yaz MDL Lead Attys Dodge Breach Of Fiduciary Duty Claim
- Shkreli Claims Bad Jury Instructions In 2nd Circ. Appeal
- ResMed Asks ITC, Calif. Court To Block Import Of Sleep Aids
- Court Can't Block Nonfinal Compounding Policy, FDA Says
- Back To School: Widener's Rod Smolla Talks Free Speech
- Tribe Can't Fault Generics Cos. For Opioid Crisis, Court Told
- Teva Worker's Discrimination Suit Stays Alive In Pa.
- Sanofi Settles SEC's International Bribery Claims For $25M
- J&J Loses Pa. Rehearing Bid Over Out-Of-State Mesh Cases
- 1st Circ. Eye Drop Decision Gets Preemption Right
- Treatment Method Patents After Fed. Circ. Vanda Ruling